CLINICAL_TRIALS
trial_result
· 2014-01-16
Clinical Trial Update: Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]
Summary
Update on a Phase 2 trial of resminostat (4SC-201) in relapsed or refractory Hodgkin lymphoma. The study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: 4SC AG | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED